B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. 2021

Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077269 Lenalidomide A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-,3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,CC 5013,CC-5013,CC5013,IMiD3 Cpd,Revimid,Revlimid
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015451 Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. B-Cell Leukemia, Chronic,B-Lymphocytic Leukemia, Chronic,Chronic Lymphocytic Leukemia,Leukemia, B-Cell, Chronic,Leukemia, Lymphocytic, Chronic,Lymphocytic Leukemia, Chronic, B-Cell,Lymphoma, Small Lymphocytic,B-Cell Chronic Lymphocytic Leukemia,B-Cell Malignancy, Low-Grade,Diffuse Well-Differentiated Lymphocytic Lymphoma,Disrupted In B-Cell Malignancy,Leukemia, B Cell, Chronic,Leukemia, Chronic Lymphatic,Leukemia, Chronic Lymphocytic,Leukemia, Chronic Lymphocytic, B-Cell,Leukemia, Lymphoblastic, Chronic,Leukemia, Lymphocytic, Chronic, B Cell,Lymphoblastic Leukemia, Chronic,Lymphocytic Leukemia, Chronic,Lymphocytic Leukemia, Chronic, B Cell,Lymphocytic Lymphoma,Lymphocytic Lymphoma, Diffuse, Well Differentiated,Lymphocytic Lymphoma, Diffuse, Well-Differentiated,Lymphocytic Lymphoma, Well Differentiated,Lymphocytic Lymphoma, Well-Differentiated,Lymphoma, Lymphocytic,Lymphoma, Lymphocytic, Diffuse, Well Differentiated,Lymphoma, Lymphocytic, Diffuse, Well-Differentiated,Lymphoma, Lymphocytic, Well Differentiated,Lymphoma, Lymphocytic, Well-Differentiated,Lymphoma, Lymphoplasmacytoid, CLL,Lymphoma, Small Lymphocytic, Plasmacytoid,Lymphoma, Small-Cell,Lymphoplasmacytoid Lymphoma, CLL,Small-Cell Lymphoma,B Cell Chronic Lymphocytic Leukemia,B Cell Leukemia, Chronic,B Cell Malignancy, Low Grade,B Lymphocytic Leukemia, Chronic,B-Cell Leukemias, Chronic,B-Cell Malignancies, Low-Grade,B-Lymphocytic Leukemias, Chronic,CLL Lymphoplasmacytoid Lymphoma,CLL Lymphoplasmacytoid Lymphomas,Chronic B-Cell Leukemia,Chronic B-Cell Leukemias,Chronic B-Lymphocytic Leukemia,Chronic B-Lymphocytic Leukemias,Chronic Lymphatic Leukemia,Chronic Lymphatic Leukemias,Chronic Lymphoblastic Leukemia,Chronic Lymphoblastic Leukemias,Chronic Lymphocytic Leukemias,Diffuse Well Differentiated Lymphocytic Lymphoma,Disrupted In B Cell Malignancy,Leukemia, Chronic B-Cell,Leukemia, Chronic B-Lymphocytic,Leukemias, Chronic B-Cell,Leukemias, Chronic B-Lymphocytic,Leukemias, Chronic Lymphatic,Leukemias, Chronic Lymphoblastic,Low-Grade B-Cell Malignancies,Low-Grade B-Cell Malignancy,Lymphatic Leukemia, Chronic,Lymphatic Leukemias, Chronic,Lymphoblastic Leukemias, Chronic,Lymphocytic Leukemias, Chronic,Lymphocytic Lymphoma, Small,Lymphocytic Lymphomas,Lymphocytic Lymphomas, Small,Lymphocytic Lymphomas, Well-Differentiated,Lymphoma, CLL Lymphoplasmacytoid,Lymphoma, Small Cell,Lymphoma, Well-Differentiated Lymphocytic,Lymphomas, CLL Lymphoplasmacytoid,Lymphomas, Lymphocytic,Lymphomas, Small Lymphocytic,Lymphomas, Small-Cell,Lymphomas, Well-Differentiated Lymphocytic,Lymphoplasmacytoid Lymphomas, CLL,Malignancies, Low-Grade B-Cell,Malignancy, Low-Grade B-Cell,Small Cell Lymphoma,Small Lymphocytic Lymphoma,Small Lymphocytic Lymphomas,Small-Cell Lymphomas,Well-Differentiated Lymphocytic Lymphoma,Well-Differentiated Lymphocytic Lymphomas
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma

Related Publications

Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
April 2009, Leukemia research,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
August 2010, Clinical journal of oncology nursing,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
March 2018, Blood,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
September 2013, Blood,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
January 2015, International journal of clinical and experimental pathology,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
January 2000, Ryoikibetsu shokogun shirizu,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
November 2017, Blood,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
April 2018, Blood,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
August 2015, American journal of clinical pathology,
Moritz Fürstenau, and Anna Maria Fink, and Anke Schilhabel, and Jonathan Weiss, and Sandra Robrecht, and Robert Eckert, and Javier de la Serna, and Marta Crespo, and Marta Coscia, and Candida Vitale, and Sebastian Böttcher, and Gesche Weppner, and Matthias Ritgen, and Stephan Stilgenbauer, and Eugen Tausch, and Kirsten Fischer, and Michael Hallek, and Barbara Eichhorst, and Monika Brüggemann, and Carmen D Herling
July 1995, Leukemia & lymphoma,
Copied contents to your clipboard!